IS ISRG Intuitive Surgical Inc. Loading... : Bullish and Bearish Analyst Opinions

Buy ISRG as Piper Sandler field checks confirm bear concerns are overblown — DV5 driving higher utilization without cannibalizing Xi volumes, ASC expansion and cardiovascular procedures are incremental growth drivers, and the company beat top/bottom line last quarter; shares dropped below $400 despite consensus PTs of $520–$651.

Long quality compounder names ISRG, LLY, MA on the thesis that as AI stocks price earnings further out, these high-quality non-AI growers are increasingly attractive on a relative basis and are being ignored by the market.

Buy quality non-AI compounders as AI stocks price growth further out, making established growth names like ISRG, LLY, and MA relatively more attractive on a forward-growth-priced-in basis.

Buy ISRG on price dislocation below $400 despite Piper Sandler's $580 PT; razor-and-blade recurring revenue model, 11,000 installed systems, 10M+ procedures create durable data moat with AI/robotics tailwinds supporting consistent YoY sales growth.

Buy ISRG as the best healthcare equity play; robotic surgical equipment avoids pharma regulatory/safety risk, and the strong competitive moat justifies a premium valuation despite elevated multiples.

Speaker observes ISRG's autonomous robotics opportunity is underappreciated by the market; no position disclosed, no specific catalyst or entry point stated.

Long medtech and digital health names as rising semiconductor content in medical devices drives growth in imaging, monitoring, robotics, and wearables.

The author implies that non-AI names are broken and will be crushed to zero multiples, signaling a bearish rotation out of traditional stocks into AI.

The author expresses frustration with market valuations and poses a rhetorical question about selling AI positions to buy non-AI names, but provides no explicit forward-looking directional call.

The author poses a rhetorical question about valuation multiples for non-AI names versus selling AI positions, but offers no explicit directional view or trade recommendation.

The tweet shares a crowdsourced list of humanoid robotics exposure tickers and mentions names that appeared most frequently, but it only states an intention to start due diligence without expressing a forward-looking directional view on any specific security.

Fejau expresses optimism about AI in healthcare after Demis Hassabis announces $2.1B funding for Isomorphic Labs to accelerate drug discovery and solve disease.

Intuitive Surgical better than Korean robotics

The tweet is a vague reply referencing homework for ISRG without any directional opinion or market impact analysis.

The author notes that ISRG will manage through semiconductor component cost inflation following price increases by TXN and NXPI, but advises understanding the pieces of the spreading cost inflation.

The author notes that many may underestimate the analog componentry in robotics, highlighting Texas Instruments and Analog Devices as key suppliers without expressing a directional view.

Intuitive threatened by competitors

ISRG’s FCF grew 74% in Q1 2026, and TTM FCF yield is 1.7% on a $170B market cap; stock price has risen 250% vs. FCF growth of 295% from the 2022 trough. This relative underperformance of price vs. fundamentals creates a potential re-rating opportunity if growth continues, offering a margin of safety even if sector headwinds persist. The author sees a reasonable risk/reward at current levels, with valuation at multi-year lows, suggesting a medium-term long entry for patient investors. Further sector-wide diagnostic/med-tech drawdowns; macro slowdown impacting procedure volumes; chart support failure below $440 could trigger more selling.

Buy secular growth outside of AI.

Bearish view on DXCM, RMD, and ISRG because accelerating declines in bariatric procedures for ISRG signal that GLP-1 drugs are reducing demand for related medical devices and services, extending to diabetes management and respiratory care.

Buy ISRG as Q1 results show strong margin expansion and record buybacks, while the stock trades at a historically low forward P/E with an AI-enabled product catalyst on the horizon.

The author is bearish on ISRG due to expected margin compression from rising semiconductor and memory costs, which they estimate could be a 25-50 bps headwind to hardware gross margins by year-end 2026.

Wellum suggests looking for businesses that will "profit from efficiencies" of AI, naming Amazon, Intuitive Surgical, and ServiceNow. Beyond the chipmakers, the real value of AI lies in productivity gains. These companies are integrating AI to lower costs (Amazon), improve healthcare outcomes (Intuitive Surgical), or streamline enterprise workflows (ServiceNow), which drives margin expansion. LONG. These are the "users" of AI that will monetize the technology through efficiency. High valuations; execution risk in AI integration.